Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Biochemical Reagents >  Agonist Inhibitors >  GDC-0810(ARN-810)

GDC-0810(ARN-810)

Basic information Safety Supplier Related

GDC-0810(ARN-810) Basic information

Product Name:
GDC-0810(ARN-810)
Synonyms:
  • (E)-3-(4-((E)-2-(2-CHLORO-4-FLUOROPHENYL)-1-(1H-INDAZOL-5-YL)BUT-1-EN-1-YL)PHENYL)ACRYLIC ACID
  • GDC-0810 (Brilanestrant)
  • GDC-0810(ARN-810)
  • GDC-0810
  • (E)-3-[4-[(E)-2-(2-Chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl]phenyl]-2-propenoic acid
  • ARN-810
  • ARN-810;BRILANESTRANT
  • CS-2080
CAS:
1365888-06-7
MF:
C26H20ClFN2O2
MW:
446.9
Mol File:
1365888-06-7.mol
More
Less

GDC-0810(ARN-810) Chemical Properties

Boiling point:
622.8±55.0 °C(Predicted)
Density 
1.342±0.06 g/cm3(Predicted)
solubility 
DMSO:89.0(Max Conc. mg/mL);199.15(Max Conc. mM)
Ethanol:89.0(Max Conc. mg/mL);199.15(Max Conc. mM)
form 
A solid
pka
13.94±0.40(Predicted)
color 
White to off-white
More
Less

GDC-0810(ARN-810) Usage And Synthesis

Uses

Brilanestrant is an orally bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts. GDC-0810 functions by binding to the estrogen receptor, inducing a conformational change resulting in the degradation of the receptor. GDC-0810 or ARN-810 demonstrates robust activity in models of tamoxifen-sensitive and tamoxifen-resistant breast cancer, and is currently in clinical trials in women with locally advanced or metastatic estrogen receptor-positive breast cancer.

in vivo

The pharmacokinetic profile of Brilanestrant (ARN-810) shows it is a olw clearance molecule across species, with good bioavailability (40%-60%). Brilanestrant (ARN-810) (3 mg/kg, p.o.) shows substantial tumor-growth inhibition in a tamoxifen-sensitive MCF-7 xenograft model, while at the highest dose of 100 mg/kg/day, all animals show tumor regression of more than 50% without weight loss[1].Brilanestrant (ARN-810) exhibits low clearance (11 mL/min/kg) and 61% oral bioavailability. Brilanestrant (ARN-810) (1-100 mg/kg/day, p.o.) displays dose dependent efficacy in the MCF7 xenograft model[2].

GDC-0810(ARN-810)Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Chembest Research Laboratories Limited
Tel
+86-21-20908456
Email
sales@BioChemBest.com
WUHAN SUN-SHINE BIO-TECHNOLOGY Co., Ltd.
Tel
17702719238 18971495150;
Email
sales@sun-shinechem.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
More
Less

GDC-0810(ARN-810)(1365888-06-7)Related Product Information